Protalix BioTherapeutics
PLX
44 hedge funds and large institutions have $59.3M invested in Protalix BioTherapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 43 → 44 (+1)
0.06% more ownership
Funds ownership: 3.38% → 3.43% (+0.06%)
22% less capital invested
Capital invested by funds: $76.5M → $59.3M (-$17.2M)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $147K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$458K |
| 3 |
D.E. Shaw & Co
New York
|
+$210K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$205K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$563K |
| 2 |
DAM
Deltec Asset Management
New York
|
-$466K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$453K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$387K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$322K |
PLX Hedge Fund Activity: Q4 2014 in Review
44 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2014, worth a combined $59.3M — down 22% from $76.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PLX positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 14 trimmed.
The largest buyer was California Public Employees Retirement System, adding an estimated $1.1M. The largest seller was Deutsche Bank, cutting an estimated $563K.
- 44 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2014, up from 43 in Q3 2014.
- Funds reported $59.3M of Protalix BioTherapeutics stock for Q4 2014, down 22% quarter-over-quarter.
- 9 funds opened new Protalix BioTherapeutics positions in Q4 2014 and 7 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2014 was California Public Employees Retirement System, an estimated $1.1M added.
- The largest Protalix BioTherapeutics seller in Q4 2014 was Deutsche Bank, an estimated $563K sold.
Based on aggregated 13F filings for Q4 2014.